RBFC
KRYS icon

Roman Butler Fullerton & Co’s Krystal Biotech KRYS Stock Holding History

Roman Butler Fullerton & Co’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,125
Closed -$325K – 276
2025
Q4 		$325K Buy
+1,125
New +$237K 0.09% 212
2025
Q2 		– Sell
-3,867
Closed -$654K – 258
2025
Q1 		$654K Buy
+3,867
New +$650K 0.25% 98

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Roman Butler Fullerton & Co's KRYS Position: Q1 2026 in Review

Roman Butler Fullerton & Co sold out of Krystal Biotech (KRYS) in Q1 2026, closing a stake of 1,125 shares — an estimated $325K sold.

Roman Butler Fullerton & Co first reported a position in KRYS in Q1 2025 and held it in 2 quarters. The position peaked at $654K in Q1 2025. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Roman Butler Fullerton & Co reported no remaining Krystal Biotech position as of Q1 2026 after selling out during the quarter.
  • Roman Butler Fullerton & Co sold 1,125 Krystal Biotech shares in Q1 2026, an estimated $325K.
  • Roman Butler Fullerton & Co first reported a position in Krystal Biotech in Q1 2025 and held it in 2 quarters.
  • Roman Butler Fullerton & Co's Krystal Biotech position peaked at $654K in Q1 2025.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Roman Butler Fullerton & Co's 13F filing for Q1 2026, filed 30 Apr 2026.